November 2024 decisions news release
The Scottish Medicines Consortium (SMC), which advises on newly licensed medicines for use by NHSScotland, has today (Monday 11 November) published advice on seven medicines.
Axicabtagene ciloleucel (Yescarta®) was accepted for the treatment of adult patients with diffuse large B-cell lymphoma or high-grade B-cell lymphoma, types of blood cancers, when they have received only one line of therapy.
Lebrikizumab (Ebglyss®) was accepted for the treatment of adults and children 12 years and older with moderate to severe atopic dermatitis, a type of eczema.
Quizartinib (Vanflyta®) was accepted to treat adult patients with newly diagnosed acute myeloid leukaemia where the cancer cells have a particular mutation.
Linzagolix (Yselty®) was accepted for treating adults with moderate to severe symptoms from uterine fibroids, benign growths in the womb.
Somapacitan (Sogroya) was accepted for the treatment of children and adolescents with growth hormone deficiency.
Tenecteplase (Metalyse®) was accepted to treat adults who have suffered a stroke caused by a blockage in a blood vessel, known as an ischaemic stroke.
Pembrolizumab (Keytruda®) used together with chemotherapy before surgery and alone after surgery, was not recommended for the treatment of adults with non-small cell lung cancer who are at high risk of recurrence following surgery.
SMC Chair Dr Scott Muir said: “The committee is pleased to be able to accept these new medicines for use by NHSScotland.
“The committee heard from patient representatives about the heavy symptom burden of lymphoma and the expected benefits axicabtagene ciloleucel could bring.
“Patient group representatives shared the substantial impact that atopic dermatitis can have on those affected. Our decision on lebrikizumab provides another treatment option which may allow some patients to better manage their condition.
“The committee was not able to accept pembrolizumab for the treatment of non-small cell lung cancer in this setting, due to the uncertainties in the evidence presented when compared to current treatments.”